LVZ Inc. Has $337,000 Position in HCA Healthcare, Inc. (NYSE:HCA)

LVZ Inc. lifted its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 21.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,124 shares of the company’s stock after acquiring an additional 195 shares during the period. LVZ Inc.’s holdings in HCA Healthcare were worth $337,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Assetmark Inc. lifted its position in HCA Healthcare by 441.8% during the fourth quarter. Assetmark Inc. now owns 9,936 shares of the company’s stock worth $2,982,000 after purchasing an additional 8,102 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of HCA Healthcare by 4.2% in the 4th quarter. Victory Capital Management Inc. now owns 140,706 shares of the company’s stock valued at $42,233,000 after purchasing an additional 5,703 shares in the last quarter. Keybank National Association OH raised its holdings in shares of HCA Healthcare by 7.9% during the 4th quarter. Keybank National Association OH now owns 2,755 shares of the company’s stock worth $827,000 after buying an additional 201 shares in the last quarter. Cornerstone Investment Partners LLC grew its position in HCA Healthcare by 11.3% in the fourth quarter. Cornerstone Investment Partners LLC now owns 241,163 shares of the company’s stock valued at $72,385,000 after acquiring an additional 24,483 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its stake in shares of HCA Healthcare by 25.1% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 1,923 shares of the company’s stock valued at $574,000 after purchasing an additional 386 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

Insider Activity

In other HCA Healthcare news, SVP Jennifer Berres sold 9,533 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $322.59, for a total value of $3,075,250.47. Following the sale, the senior vice president now directly owns 15,412 shares in the company, valued at $4,971,757.08. This represents a 38.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.60% of the company’s stock.

HCA Healthcare Stock Performance

NYSE HCA opened at $312.32 on Wednesday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $417.14. The company has a debt-to-equity ratio of 69.07, a quick ratio of 0.97 and a current ratio of 1.08. The company has a 50-day simple moving average of $315.46 and a 200 day simple moving average of $348.37. The company has a market capitalization of $77.56 billion, a PE ratio of 14.22, a price-to-earnings-growth ratio of 1.10 and a beta of 1.64.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, January 24th. The company reported $6.22 earnings per share for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.16% and a return on equity of 586.47%. During the same quarter last year, the firm earned $5.90 earnings per share. On average, research analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 17th will be paid a $0.72 dividend. The ex-dividend date is Monday, March 17th. This represents a $2.88 annualized dividend and a yield of 0.92%. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.66. HCA Healthcare’s dividend payout ratio (DPR) is currently 13.11%.

Analyst Ratings Changes

HCA has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $405.00 price objective on shares of HCA Healthcare in a research report on Monday, January 27th. Morgan Stanley cut their target price on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Barclays reduced their price objective on shares of HCA Healthcare from $392.00 to $366.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Truist Financial lowered their price objective on HCA Healthcare from $430.00 to $390.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $380.00 target price on shares of HCA Healthcare in a report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.